Select publications

Baker SD et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002;94(24):1883-8. Abstract

Biganzoli L et al. Moving forward with capecitabine: A glimpse of the future. Oncologist 2002;7(Suppl 6):29-35. Abstract

Budman DR et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90(16):1205-11. Abstract

Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Henderson IC et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21(6):976-83. Abstract

Lyman GH et al. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 2003;21(24):4524-31. Abstract

Madarnas Y et al. Are medical oncologists biased in their treatment of the large woman with breast cancer? Breast Cancer Res Treat 2001;66(2):123-33. Abstract

Martin M et al. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 2003;Abstract 43.

Mouridsen H et al. Phase III study of docetaxel 100 versus 75 versus 60 mg/m2 as second line chemotherapy in advanced breast cancer. Breast Cancer Res Treat 2002;Abstract 327.

Nabholtz JM et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21(6):968-75. Abstract

O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract

O’Shaughnessy JA et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12(9):1247-54. Abstract

Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: Science, myth, or habit? J Clin Oncol 1998;16(7):2297–8. No abstract available

Rosner GL et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: Results from cancer and leukemia group B study 8541. J Clin Oncol 1996;14(11):3000-8. Abstract

Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 2001;19(2):171-7. Abstract

Seidman AD et al. Single-agent capecitabine: A reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002;7(Suppl 6):20-8. Abstract

Smith G et al. Project ChemoInsight reveals physician practice patterns for adjuvant breast cancer chemotherapy, and compares the dose intensity of CMF, AC, and CAF. Proc ASCO 1999;Abstract 296.

Venturini M et al. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer 2003;97(5):1174-80. Abstract

Home · Search